Full Press Release Details
ADC Therapeutics to Host Fourth Quarter and Year-End
Financial Results Conference Call on March 3,
Lausanne, Switzerland,
February 24, 2022 - ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those
affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and
solid tumors, today announced that it will host a conference call and live webcast on Thursday, March 3, 2022 at 8:30 a.m. ET to report
financial results for the fourth quarter and year-end 2021 and provide business updates.
call, please dial 833-303-1198 (domestic) or +1 914-987-7415 (international) and provide conference
ID 8189237. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section
of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.
About ADC Therapeutics
(NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted
antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm
for patients with hematologic malignancies and solid tumors.
CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse
large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents.
Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase
1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing
clinical and preclinical development.
is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information,
please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
ZYNLONTA is a registered trademark
of ADC Therapeutics SA.